ARCT241220P65000
- 45.70
- 0.000.00%
Arcturus Therapeutics Newsroom
Arcturus Therapeutics to Present at Jefferies London Healthcare Conference
Express News | Meiji Seika Pharma Announces Investment in Arcalis, Inc.
Meiji Seika Pharma Announces Investment in ARCALIS, Inc.
Arcturus Therapeutics: Overcoming Challenges and Poised for European Expansion
We're Not Very Worried About Arcturus Therapeutics Holdings' (NASDAQ:ARCT) Cash Burn Rate
Arcturus Gets FDA Clearance for H5N1 Avian Flu Vaccine Study
Express News | Arcturus Therapeutics Holdings Inc - Study to Enroll Approximately 200 Healthy Adults in U.S.
Express News | Arcturus Therapeutics Receives Clearance From FDA to Begin H5N1 Pandemic Flu Vaccine Clinical Trial
Arcturus Therapeutics (ARCT): Impressive Pipeline and Potentially Promising Future
H.C. Wainwright Maintains Arcturus Therapeutics(ARCT.US) With Buy Rating, Maintains Target Price $63
Arcturus Therapeutics: Strong Buy Rating Backed by Promising Kostaive Sales and Promising Pipeline Developments
Arcturus Therapeutics Holdings Inc. (ARCT) Q3 2024 Earnings Call Transcript Summary
Arcturus Therapeutics Holdings Inc. (ARCT) Q3 2024 Earnings Call Transcript
Arcturus Therapeutics | 10-Q: Q3 2024 Earnings Report
Arcturus Therapeutics: Q3 Earnings Snapshot
Arcturus Therapeutics GAAP EPS of -$0.26 Beats by $0.88, Revenue of $41.67M Beats by $5.08M
Earnings Flash (ARCT) ARCTURUS THERAPEUTICS HOLDINGS Posts Q3 Revenue $41.7M
Express News | Arcturus Therapeutics Q3 Collaboration Revenue USD 38.815 Million
Express News | Arcturus Therapeutics Q3 Net Income USD -6.903 Million Vs. IBES Estimate USD -35.3 Million
Arcturus Therapeutics 3Q Loss/Shr 26c >ARCT